Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 2/20 | 0.32 |
| ▸ | F3 | P13726 | 2/20 | 0.32 |
| ▸ | ALAD | P13716 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607694 | 0.80 | CES2 (0.38) | TSHRALOX15ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL3609237 | 0.80 | NPC1 (0.38) | TSHRALOX15ALDH1A1CASP1SMN1; SMN2 | |
| SCHEMBL3617819 | 0.75 | ALDH1A1 (0.40) | ALOX15ALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL1196135 | 0.75 | ABL1 (0.43) | TSHRALDH1A1CASP1SMN1; SMN2HSD17B10 | |
| SCHEMBL6204341 | 0.75 | ALDH1A1 (0.52) | TSHRALOX15ALDH1A1HSD17B10 | |
| SCHEMBL2780243 | 0.74 | TSHR (0.50) | TSHRALOX15SRD5A2ALDH1A1TP53 | |
| SCHEMBL1196438 | 0.74 | TMPRSS4 (0.50) | TSHRALOX15ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL4957915 | 0.73 | TSHR (0.48) | TSHRALOX15SRD5A2ALDH1A1TP53 | |
| SCHEMBL4030667 | 0.73 | TPMT (0.44) | TSHRALOX15TP53CA1CA2 | |
| SCHEMBL16267153 | 0.73 | ALDH1A1 (0.44) | SRD5A2ALDH1A1SMN1; SMN2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| CN-113105411-A | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2021-07-13 | — | — | CN | claimed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | claimed |
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-25 | — | — | US | claimed |
| US-8252830-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | claimed |
| EP-1981854-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-01 | — | — | EP | claimed |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-03 | — | — | US | claimed |
| US-5948813-A | Method of preventing allograft rejection | PFIZER INC. (US) | 1999-09-07 | — | — | US | claimed |
| EP-0912549-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-05-06 | — | — | EP | claimed |
| JP-2765757-B2 | — | — | 1998-06-18 | — | — | JP | claimed |
| EP-0836850-A2 | Method of preventing allograft rejection | PFIZER INC. (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1997048694-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-12-24 | — | — | WO | claimed |
| US-5684046-A | LEUKOTRIENE B4 ANTAGONIST AS ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | PFIZER INC (US) | 1997-11-04 | — | — | US | claimed |
| EP-0623123-B1 | Benzopyran and related LTB4-antagonists | PFIZER (US) | 1997-04-23 | — | — | EP | claimed |
| US-5552435-A | ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS | PFIZER INC. (US) | 1996-09-03 | — | — | US | claimed |
| EP-0623123-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | claimed |
| WO-1993015067-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | TSHR 1338/4885ALOX15 2971/4885SRD5A2 3840/4885 |
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SOST, HDAC5, PTH1R | TSHR 1218/4885ALOX15 1854/4885SRD5A2 329/4885 |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | FH, HDGF, HRH4 | TSHR 1288/4885ALOX15 1512/4885SRD5A2 130/4885 |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | TSHR 1338/4885ALOX15 2971/4885SRD5A2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.